With Only Grant Revenue Trickling In, Helicos' R&D Costs Deepen Q3 Loss | GenomeWeb
NEW YORK (GenomeWeb News) — In its second quarterly earnings report since its initial public offering in May, Helicos today said it gained minimal revenue from grants while R&D spending rose 73 percent and its net loss grew by 68 percent compared to the prior-year period.
 
Total receipts for its third quarter ended Sept. 30 were $230,000 while the company claimed no revenue for the third quarter of 2006.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: flu susceptibility and Y chromosome variation in mice, deletion tied to epilepsy in dog breed, and more.

Sequencing is enabling the roots of some rare diseases to be determined, the Financial Times reports.

Proove Biosciences had allegedly been paying doctors to perform its opioid risk and other genetic tests, Stat News reports.

A floated budget plan could see non-military discretionary spending in the US — which includes science agency funding — fall, the New York Times reports.